Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) status demonstrating little predictive utility...

Descripción completa

Detalles Bibliográficos
Autores principales: Labriola, Matthew Kyle, Zhu, Jason, Gupta, Rajan, McCall, Shannon, Jackson, Jennifer, Kong, Eric F, White, James R, Cerqueira, Gustavo, Gerding, Kelly, Simmons, John K, George, Daniel, Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206964/
https://www.ncbi.nlm.nih.gov/pubmed/32221016
http://dx.doi.org/10.1136/jitc-2019-000319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206964/
https://www.ncbi.nlm.nih.gov/pubmed/32221016
http://dx.doi.org/10.1136/jitc-2019-000319

Ejemplares similares